[ad_1]
Randox Laboratories (Crumlin, UK) has launched its new SARS-CoV-2 IgG test, using the proprietary Randox Biochip technology to simultaneously detect IgG antibodies that are reactive to the two leading COVID-19 diagnostic antigens – Spike Receptor Binding Domain ( RBD) and nucleocapsid protein (NP).
Maximum test sensitivity is ensured by simultaneous detection of RBD and NP-only responders, making it superior to commercially available COVID-19 IgG tests that are based on RBD or NP alone, from which results can be produced. false negatives. The Randox SARS-CoV-2 IgG Matrix (RBD & NP) provides clinicians the opportunity to discriminate between vaccinated and naturally COVID-19 infected individuals.
The Randox SARS-CoV-2 IgG Matrix (RBD & NP) has been developed for Evidence Investigator, a semi-automatic benchtop immunoassay analyzer that delivers accurate results in just 1.5 hours. The new matrix has a specificity of 99.5% and a sensitivity of 100% more than 14 days after PCR testing with a sensitivity of 92.3% 0-14 days after PCR confirmation. The Randox SARS-CoV-2 Antibody Array will also include a calibrator and controls are available upon request.
“When there is little or no access to molecular testing, serological testing provides a means to quickly classify suspected COVID-19 cases, enabling proper case management and guiding public health measures, such as quarantine or self-isolation, “said Lynsey Adams. , Randox Clinical Marketing Manager. “The new Randox SARS-CoV-2 IgG (RBD & NP) matrix provides a unique insight into disease severity, is an established method of indirect disease diagnosis, and facilitates epidemiological surveillance as the COVID pandemic progresses. 19 “.
